News from esperion therapeutics

Jan 07, 2013, 06:00 ET

Esperion Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes

 Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced...

Jan 04, 2013, 09:00 ET

Tim Mayleben Named President And CEO Of Esperion Therapeutics

 Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today...

Jan 03, 2013, 15:51 ET

Esperion To Present At 31st Annual J.P. Morgan Healthcare Conference

 Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that...

Apr 09, 2012, 12:50 ET

Noah Rosenberg, MD, Joins Esperion Therapeutics as Chief Medical Officer

 Esperion Therapeutics, Inc. today announced the appointment of Noah Rosenberg, MD, as its chief medical officer (CMO).  Dr. Rosenberg...

Mar 26, 2012, 09:00 ET

Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002

 Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for...

May 02, 2011, 09:00 ET

Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and...

Jan 06, 2011, 08:30 ET

Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and...

Jun 21, 2010, 09:00 ET

TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and...

Jun 14, 2010, 09:00 ET

Esperion Therapeutics and Cleveland Clinic Establish Collaboration for Research Related to HDL Therapies

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and...

Nov 13, 2009, 11:35 ET

Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and...

Jan 27, 2004, 00:00 ET

Esperion Receives Fifth U.S. Patent for Small Molecule Program

ANN ARBOR, Mich., Jan. 27 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the...

Jan 22, 2004, 00:00 ET

Esperion Reports Financial Results for the Quarter and Year Ended December 31, 2003

ANN ARBOR, Mich., Jan. 22 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the...

Jan 13, 2004, 00:00 ET

Esperion Announces License Agreement With Nippon Chemiphar To Develop New Therapies Based on PPAR Delta Agonists

ANN ARBOR, Mich., Jan. 13 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR) has entered into a license agreement with Nippon...

Jan 09, 2004, 00:00 ET

Esperion to Present at JPMorgan Healthcare Conference

ANN ARBOR, Mich., Jan. 9 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the...

Jan 08, 2004, 00:00 ET

Esperion Announces Settlement of Short-Swing Profit Lawsuit

ANN ARBOR, Mich., Jan. 8 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced that the Durus Life Sciences Master...

Dec 16, 2003, 00:00 ET

Esperion Reports Positive Results for Second Phase 1 Study of ETC-642

ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the completion of a second Phase 1...

Dec 04, 2003, 00:00 ET

Esperion Announces Positive Results of Phase 1 Study of ETC-1001

ANN ARBOR, Mich., Dec. 4 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the successful completion of a...

Nov 10, 2003, 00:00 ET

Esperion to Present at the CIBC World Markets Healthcare Conference

ANN ARBOR, Mich., Nov. 10 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the...

Nov 04, 2003, 00:00 ET

Esperion Announces Publication of Results From Phase 2 Study of ETC-216 and Upcoming Conference Call

ANN ARBOR, Mich., Nov. 4 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the results of a study providing...

Nov 03, 2003, 00:00 ET

Esperion to Hold Conference Call to Provide Update On Findings From Study of ETC-216

ANN ARBOR, Mich., Nov. 3 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. will hold a conference call to provide detailed findings related...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge